.png "Genomic Health (NASDAQ: GHDX)")
Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Genomic Health (GHDX) today and set a price target of $82. The company’s shares closed yesterday at $70.79, close to its 52-week high of $73.95.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 16.5% and a 59.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Quanterix Corporation, and Idexx Laboratories.
Genomic Health has an analyst consensus of Moderate Buy, with a price target consensus of $70.
See today’s analyst top recommended stocks >>
Genomic Health’s market cap is currently $2.54B and has a P/E ratio of 643.55. The company has a Price to Book ratio of 11.27.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is neutral on the stock. Most recently, in September 2018, Fred E. Cohen, a Director at GHDX sold 8,250 shares for a total of $507,375.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning.
